Comparing Two Treatments for Malaria in Ghanaian Children
Author Information
Author(s): Adjei George O, Kurtzhals Jorgen A, Rodrigues Onike P, Alifrangis Michael, Hoegberg Lotte C G, Kitcher Emmanuel D, Badoe Ebenezer V, Lamptey Roberta, Goka Bamenla Q
Primary Institution: University of Ghana Medical School
Hypothesis
How do artesunate-amodiaquine and artemether-lumefantrine compare in efficacy and safety for treating uncomplicated malaria in children?
Conclusion
Both treatments were effective for malaria in children, but there are concerns about the prevalence of drug-resistant parasites.
Supporting Evidence
- 97.1% of subjects treated with AM-L had adequate clinical response on day 14.
- 94.2% of subjects treated with AS+AQ had adequate clinical response on day 28.
- The incidence of malaria attacks was similar between the two treatment groups over one year.
- Adverse events were mild and similar in both treatment groups.
- No signs of hearing impairment or abnormal neurological signs were observed during follow-up.
Takeaway
The study looked at two medicines for treating malaria in kids and found both worked well, but some parasites might not be affected by one of the medicines.
Methodology
Children aged 6 months to 14 years with uncomplicated malaria were randomly assigned to receive either AS+AQ or AM-L and followed for one year.
Potential Biases
Potential biases in treatment allocation and follow-up due to loss of participants.
Limitations
The study had limited statistical power to detect rare side effects and challenges in evaluating neurological function in younger children.
Participant Demographics
Children aged 6 months to 14 years, predominantly from low socio-economic backgrounds in urban Ghana.
Statistical Information
P-Value
0.93
Statistical Significance
p = 0.93
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website